Oruka Therapeutics (ORKA) Price & Analysis

Compare

654 Followers

ORKA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.49 - $31.13

Previous CloseN/A

Volume71.58K

Average Volume (3M)294.59K

Market Cap

$738.83M

Enterprise Value$148.75M

Total Cash (Recent Filing)$328.41M

Total Debt (Recent Filing)$2.33M

Price to Earnings (P/E)―

Beta0.91

Next Earnings

Nov 12, 2025

EPS Estimate

-0.58

Last Dividend Ex-Date

Aug 29, 2024

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.46

Shares Outstanding48,384,150

10 Day Avg. Volume582,610

30 Day Avg. Volume294,588

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.20

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-4.80K

Enterprise Value/Ebitda-1.50

Forecast

1Y Price Target

$45.83

Price Target Upside201.51% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Drug EfficacyORKA-001 demonstrated a Cmax that exceeded Skyrizi at an equivalent dose, supporting its potential to deliver greater efficacy.

Financial PositionOruka Therapeutics announced a $180M financing that extends their cash runway for at least 1 year past their Phase 2b and Phase 2 readouts in 2027.

Market PotentialORKA holds scarcity value in the psoriasis market with its lead candidates and combination therapies showing potential for strong efficacy and convenience.

Bears Say

Clinical RisksTesting higher exposures in psoriasis is de-risked by extensive clinical experience with high-dose IL-23p19 regimens in IBD.

CompetitionORKA-002 is positioned to become a strong competitor to currently marketed agents, indicating its potential for significant future growth but also the challenges of competing in a crowded market.

Regulatory ChallengesORKA announced FDA clearance to initiate the Phase 2a EVERLAST-A trial in moderate-to-severe plaque psoriasis earlier than expected, which can pose unforeseen challenges.

Oruka Therapeutics News

Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!

Earnings reports, Federal Reserve decisions, and more have the stock market on the move today. ...

10d ago

AMD

Oruka Therapeutics data hits ‘bull case’ scenario, says Clear Street

Clear Street says Oruka Therapeutics (ORKA)’ data for ORKA-001 hit the “bull case.” Initial data from the Phase...

11d ago

ORKA

Oruka Therapeutics sells 10.9M shares at $15 in private placement

Oruka Therapeutics (ORKA) announced that it has entered into a securities purchase agreement for a private investment in...

11d ago

ORKA

Oruka Therapeutics announces interim data from ORKA-001 trial at EADV

Oruka Therapeutics (ORKA) announced interim data from its Phase 1 trial of ORKA-001, the company’s long-acting IL-23p19 antibody,...

11d ago

ORKA

Oruka Therapeutics Secures $180M in Private Placement

Oruka Therapeutics ( ($ORKA) ) just unveiled an announcement. On September 17, 2025, Oruka Therapeutics announced a Securities...

5d ago

ORKA

Oruka Therapeutics initiated with a Buy at Clear Street

Clear Street analyst Kaveri Pohlman initiated coverage of Oruka Therapeutics (ORKA) with a Buy rating and $46 price...

1M ago

ORKA

Oruka Therapeutics: Promising Clinical Developments and Strong Financial Health Justify Buy Rating

David Risinger, an analyst from Leerink Partners, maintained the Buy rating on Oruka Therapeutics. The associated price target...

1M ago

ORKA

Promising Prospects for Oruka Therapeutics: Buy Rating Backed by Strong Growth and Financial Stability

Oruka Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Julian Harrison from...

2M ago

ORKA

Oruka Therapeutics Reports Q2 2025 Financial Results

ARCA biopharma, Inc. ( ($ORKA) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

ORKA

Oruka Therapeutics: Promising Clinical Developments and Strong Financial Position Justify Buy Rating

Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Oruka Therapeutics, retaining the price target of...

2M ago

ORKA

Oruka Therapeutics reports Q2 EPS (46c), consensus (43c)

“We are very pleased to have initiated our EVERLAST-A study, and we expect nearly all our sites to...

2M ago

ORKA

Oruka Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Oruka Therapeutics today and set a price target...

2M ago

ORKA

Strong Buy Recommendation for Oruka Therapeutics: Promising Pipeline and Attractive Valuation

Leerink Partners analyst David Risinger has reiterated their bullish stance on ORKA stock, giving a Buy rating on...

2M ago

ORKA

Positive Outlook for Oruka Therapeutics: ORKA-001’s Promising Phase 2a Trial and Potential Market Differentiation

In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Oruka Therapeutics, with a...

2M ago

ORKA

ORKA FAQ

What was Oruka Therapeutics’s price range in the past 12 months?

Oruka Therapeutics lowest stock price was $5.49 and its highest was $31.13 in the past 12 months.

What is Oruka Therapeutics’s market cap?

Oruka Therapeutics’s market cap is $738.83M.

When is Oruka Therapeutics’s upcoming earnings report date?

Oruka Therapeutics’s upcoming earnings report date is Nov 12, 2025 which is in 45 days.

How were Oruka Therapeutics’s earnings last quarter?

Oruka Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.49 by $0.03.

Is Oruka Therapeutics overvalued?

According to Wall Street analysts Oruka Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Oruka Therapeutics pay dividends?

Oruka Therapeutics pays a Notavailable dividend of $19.356 which represents an annual dividend yield of N/A. See more information on Oruka Therapeutics dividends here

What is Oruka Therapeutics’s EPS estimate?

Oruka Therapeutics’s EPS estimate is -0.58.

How many shares outstanding does Oruka Therapeutics have?

Oruka Therapeutics has 48,384,150 shares outstanding.

What happened to Oruka Therapeutics’s price movement after its last earnings report?

Oruka Therapeutics reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.49. Following the earnings report the stock price went up 6.897%.

Which hedge fund is a major shareholder of Oruka Therapeutics?

Currently, no hedge funds are holding shares in ORKA

Oruka Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-53.15%

Trailing 12-Months

Asset Growth

956.07%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Oruka Therapeutics

Oruka Therapeutics (ORKA) is a biotechnology company focused on developing innovative therapies for rare and complex diseases. Operating within the pharmaceutical and healthcare sectors, Oruka Therapeutics specializes in cutting-edge drug discovery and development, utilizing advanced technologies to address unmet medical needs. The company's core offerings include a pipeline of proprietary therapeutics aimed at improving patient outcomes and enhancing quality of life.

Oruka Therapeutics (ORKA) Earnings & Revenues

Historic Earnings Reports

ORKA Stock 12 Month Forecast

Average Price Target

$45.83

▲(201.51% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","57":"$57","20.25":"$20.3","32.5":"$32.5","44.75":"$44.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$56.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$45.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,20.25,32.5,44.75,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.56,18.67076923076923,21.78153846153846,24.892307692307693,28.003076923076925,31.113846153846154,34.22461538461538,37.33538461538462,40.44615384615385,43.55692307692308,46.667692307692306,49.77846153846154,52.88923076923077,{"y":56,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.56,17.888461538461538,20.216923076923077,22.545384615384616,24.873846153846152,27.20230769230769,29.53076923076923,31.85923076923077,34.18769230769231,36.51615384615385,38.84461538461539,41.17307692307692,43.50153846153846,{"y":45.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.56,17.44,19.32,21.2,23.08,24.96,26.84,28.72,30.6,32.48,34.36,36.24,38.12,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.8,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.75,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.19,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.96,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.39,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.45,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.09,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.77,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >